StephenESallanMD
Hematology • Boston, MAHematologic Oncology
Professor of Pediatrics, Dana-Farber Cancer Institute
Dr. Sallan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Avenue
Room 1642
Boston, MA 02215Phone+1 617-632-3316Fax+1 617-632-5511
Education & Training
Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1973 - 1975- Boston Children’s HospitalFellowship, Child and Adolescent Psychiatry, 1972 - 1973
Children's Hospital of PhiladelphiaResidency, Pediatrics, 1968 - 1969
St Elizabeth's Medical Center/Lemuel Shattuck HospitalInternship, Transitional Year, 1967 - 1968
Wayne State University School of MedicineClass of 1967
Certifications & Licensure
MA State Medical License 1971 - 2025- American Board of Pediatrics Pediatrics
Awards, Honors, & Recognition
- Pediatric Oncology Award American Society of Clinical Oncology, 2015
- Boston Red Sox Biomedical All-Star 2003
- Boston Magazine Castle Connolly, 2008-2013
- Join now to see all
Clinical Trials
- Treatment of Childhood Acute Lymphoblastic Leukemia: Grant Application Title: Erwinia Asparaginase in Childhood Acute Leukemia Start of enrollment: 1996 Jan 01
- Treatment of Childhood Acute Lymphoblastic Leukemia Start of enrollment: 1996 Jan 01
Publications & Presentations
PubMed
- 269 citationsAssessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, ran...Steven E. Lipshultz, Rebecca E. Scully, Stuart R. Lipsitz, Stephen E. Sallan, Lewis B. Silverman
The Lancet. Oncology. 2010-10-01 - 492 citationsChronic Progressive Cardiac Dysfunction Years After Doxorubicin Therapy for Childhood Acute Lymphoblastic LeukemiaSteven E. Lipshultz, Stuart R. Lipsitz, Stephen E. Sallan, Virginia M. Dalton, Suzanne M. Mone
Journal of Clinical Oncology. 2005-04-20 - 335 citationsLong-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, a...Steven E. Lipshultz, M. Jacob Adams, Steven D. Colan, Louis S. Constine, Eugene H. Herman
Circulation. 2013-10-22
Press Mentions
Postinduction Dexamethasone and Individualized Dosing of Asparaginase Improve Outcome in Pediatric ALLJune 10th, 2013
Intensified Chemotherapy Shows Promise for Children with Very High Risk Form of LeukemiaDecember 10th, 2012
It Takes a Lifetime to Survive Childhood CancerOctober 17th, 2023
Grant Support
- Clinical Consortia (Pediatric &Adult)National Cancer Institute2006–2010
- Therapeutic Index Of Acute Lymphoblastic LeukemiaNational Cancer Institute2000–2010
- Enhancing Treatment Outcomes In Childhood Acute Lymphocytic LeukemiaNational Cancer Institute2000–2002
- Core--Acute Lymphocytic Leukemia ConsortiaNational Cancer Institute2000–2002
- Fibroblast Growth Factor Quantification In ChildrenNational Center For Research Resources1996–2002
- Enhancing Treatment Outcomes In Childhood AllNational Cancer Institute1996–1999
- Core--All ConsortiumNational Cancer Institute1996–1999
- Maximizing The Therapeutic Index Of Childhood AllNational Cancer Institute1995–1999
- Pediatric Oncology GroupNational Cancer Institute1986–1991
Professional Memberships
- Member
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
